13 octobre 2017 11:41 AM Est – New York / Heure d’été (USA)

BUSINESS WIRE

Ncardia unterzeichnet Lizenzvertrag mit dem ersten pharmazeutischen Partner für das Patentportfolio für Krankheitsmodelle

Voir en taille réelle

Opens in new window

Formats de téléchargements

Haute résolution JPEG, 800x225, 79.9 KB
Basse résolution JPEG, 480x135, 42.2 KB
Aperçu JPEG, 144x41, 7.2 KB
Miniature JPEG, 120x34, 5.6 KB

Smart Galerie multimédia

Ncardia is a leader in standardized, validated iPSC assays for safety, phenotypic screening and disease modeling. For scientists conducting cardiovascular and neural safety and efficacy projects, Ncardia is providing tools to facilitate accelerated development of drugs, while replacing animal studies and putting a "human" aspect back into drug discovery. (Graphic: Business Wire)

Ncardia is a leader in standardized, validated iPSC assays for safety, phenotypic screening and disease modeling. For scientists conducting cardiovascular and neural safety and efficacy projects, Ncardia is providing tools to facilitate accelerated development of drugs, while replacing animal studies and putting a "human" aspect back into drug discovery. (Graphic: Business Wire)

View and Share Photo

http://www.businesswire.fr/multimedia/fr/20171013005507/de/4196664/

Partager

Email

Tous les communiqués de presse | Communiqués avec photos, clips vidéo/audio > Communiqués de presse: Ncardia unterzeichnet Lizenzvertrag mit dem ers...

Autres sites Business Wire